Spruce Biosciences, Inc.
Spruce Biosciences, Inc. is listed today as Spruce Biosciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $50 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Feb 2023 | $54 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Feb 2020 | $88 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Spruce Biosciences, Inc. had no revenue when it filed its newest notice of a funding round (Oct 2025).
SEC Form D (revenue range) · Oct 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2025
Products and services#
No products or services of Spruce Biosciences, Inc. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| HealthCap VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Omega Fund VI GP, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Omega Fund VI GP Manager, Ltd. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Omega Fund VI, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| RiverVest Venture Fund III, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| RiverVest Venture Fund III (Ohio), L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| RiverVest Venture Fund IV, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 11 investors.
Largest shareholders today
Institutions holding Spruce Biosciences, Inc. shares, as of Sep 30, 2026.
- AIGH Capital Management LLC$12 M8.70%
- Orbimed Advisors LLC$12 M8.45%
- BlackRock, Inc.$9 M6.68%
- Millennium Management LLC$7 M4.76%
- Vanguard Capital Management LLC$6 M4.15%
- Ikarian Capital, LLC$5 M3.53%
- Citadel Advisors LLC$4 M3.15%
- Geode Capital Management, LLC$3 M2.32%
- Cable Car Capital, LP$3 M2.09%
- State Street Corp$3 M2.05%
- Alyeska Investment Group, L.P.$3 M1.80%
- ADAR1 Capital Management, LLC$3 M1.80%
- Point72 Asset Management, L.P.$2 M1.54%
- Diadema Partners LP$2 M1.41%
- Eversept Partners, LP$2 M1.39%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Javier Szwarcberg | Executive officer | Oct 2025 |
| Michael Grey | Executive officer | Oct 2025 |
| Samir Gharib | Executive officer | Oct 2025 |
| Ralph William Charlton III | Executive officer | Feb 2023 |
| Richard King | Executive officer | Aug 2020 |
| Bali Muralidhar | Director | Oct 2025 |
| Daniel Spiegelman | Director | Oct 2025 |
| Javier Szwarcberg | Director | Oct 2025 |
| Kirk Ways | Director | Oct 2025 |
| Michael Grey | Director | Oct 2025 |
| Percival Barretto-Ko | Director | Oct 2025 |
| Simpson Camilla | Director | Oct 2025 |
| Tiba Aynechi | Director | Oct 2025 |
| Dina Chaya | Director | Feb 2023 |
| Camilla Simpson | Director | Aug 2020 |
| Jonas Hansson | Director | Aug 2020 |
| Niall O'Donnell | Director | Aug 2020 |
| Richard King | Director | Aug 2020 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.